+

WO2009138780A3 - Combination of an egfr inhibitor with an endocrine agent and treatment of breast cancer - Google Patents

Combination of an egfr inhibitor with an endocrine agent and treatment of breast cancer Download PDF

Info

Publication number
WO2009138780A3
WO2009138780A3 PCT/GB2009/050495 GB2009050495W WO2009138780A3 WO 2009138780 A3 WO2009138780 A3 WO 2009138780A3 GB 2009050495 W GB2009050495 W GB 2009050495W WO 2009138780 A3 WO2009138780 A3 WO 2009138780A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
breast cancer
combination
egfr inhibitor
endocrine agent
Prior art date
Application number
PCT/GB2009/050495
Other languages
French (fr)
Other versions
WO2009138780A2 (en
Inventor
Lisa Renee Bailey Iacona
Ian Smith
Mary Stuart
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Publication of WO2009138780A2 publication Critical patent/WO2009138780A2/en
Publication of WO2009138780A3 publication Critical patent/WO2009138780A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of treating hormone sensitive breast cancer, in a warm-blooded animal, such as man, that has not received prior endocrine therapy, in need of such treatment which comprises administering to said animal an effective amount of an EGFR inhibitor in combination with an effective amount of an endocrine agent suitable for use in the treatment of breast cancer. Also described are combinations and uses thereof in the method according to the invention.
PCT/GB2009/050495 2008-05-13 2009-05-11 Therapeutic treatment - 355 WO2009138780A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5272108P 2008-05-13 2008-05-13
US61/052,721 2008-05-13
US12058608P 2008-12-08 2008-12-08
US61/120,586 2008-12-08

Publications (2)

Publication Number Publication Date
WO2009138780A2 WO2009138780A2 (en) 2009-11-19
WO2009138780A3 true WO2009138780A3 (en) 2010-03-04

Family

ID=40942791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/050495 WO2009138780A2 (en) 2008-05-13 2009-05-11 Therapeutic treatment - 355

Country Status (1)

Country Link
WO (1) WO2009138780A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019211322A1 (en) * 2018-05-02 2019-11-07 Mithra Pharmaceuticals S.A. Treatment of advanced estrogen receptor positive breast cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005791A2 (en) * 2000-07-18 2002-01-24 Pharmacia Italia Spa Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
WO2005028469A1 (en) * 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
WO2007054551A1 (en) * 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005791A2 (en) * 2000-07-18 2002-01-24 Pharmacia Italia Spa Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
WO2005028469A1 (en) * 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
WO2007054551A1 (en) * 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KUREBAYASHI JUNICHI ET AL: "Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer.", BREAST CANCER (TOKYO, JAPAN) 2004, vol. 11, no. 1, 2004, pages 38 - 41, XP002542607, ISSN: 1340-6868 *
OKUBO S ET AL: "Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD 1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.", BRITISH JOURNAL OF CANCER, vol. 90, no. 1, 12 January 2004 (2004-01-12), pages 236 - 244, XP002542606, ISSN: 0007-0920 *
POLYCHRONIS ET AL: "Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 6, no. 6, 1 June 2005 (2005-06-01), pages 383 - 391, XP005008111, ISSN: 1470-2045 *

Also Published As

Publication number Publication date
WO2009138780A2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
WO2009064444A9 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2010003057A3 (en) Treating cancer
MX2019008701A (en) Combination therapy involving diaryl macrocyclic compounds.
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2008137867A3 (en) Compositions comprising mir34 therapeutic agents for treating cancer
EA201300171A1 (en) METHODS AND COMPOSITIONS FOR LIVER CANCER THERAPY
WO2012018404A3 (en) Use of her3 binding agents in prostate treatment
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
MY166014A (en) Combination therapy methods for treating proliferative diseases
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
MX394667B (en) Diarylhydantoin compounds
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
PH12012502380B1 (en) Methods of treatment of pancreatic cancer
WO2008094708A3 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2008015775A (en) Compounds and compositions for treatment of cancer.
WO2012078867A3 (en) Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2009016488A3 (en) Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
WO2012170742A3 (en) Treatment and prevention of cancer with hmgb1 antagonists
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
WO2011056566A3 (en) Compounds and methods for treatment of cancer
WO2011153243A3 (en) Anti-angiogenesis therapy for treating gastric cancer
WO2008115478A3 (en) Method of cancer detection and treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09746097

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09746097

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载